AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04819386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active vision therapy sessions with the NEIVATECH Virtual Reality-based system
Description: The active visual therapy sessions with the NEIVATECH Virtual Reality-based system will be 18 in total, will have an average duration of half an hour and will be distributed over a month as follows: 5 sessions in the first two weeks after enrollment (Monday to Friday) and 4 sessions in the next two weeks (Monday to Thursday).
Study NCT04704076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESVS
Description: Breastfeeding with up to 59-mL formula daily for the first 30 days, followed by exclusive breastfeeding through 6 months of age
Study NCT04124315 — intervention group
Intervention type: OTHER
Intervention: Accelerometry
Description: Patients will be given accelerometers at this visit and informed on how to use them (e.g., wear on the ankle during waking hours, upright, etc).
Study NCT04124315 — intervention group
Intervention type: OTHER
Intervention: Daynamica app
Description: Participants will be asked to record location/activity on the app in order to characterize activity patterns both inside and outside of the hospital SET setting.
Study NCT04704076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exclusive breastfeeding
Description: Breastfeeding exclusively without any other food or fluid except vitamins, minerals and medications through 6 months of age
Study NCT05111769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human brain natriuretic peptide
Description: 1. To determine the effect of rhBNP on hemodynamics in sepsis based on PiCCO hemodynamic monitoring; 2. To collect and sort out the relevant data to determine the effects of rhBNP on cardiac function and kidney function, including cardiac ultrasound, kidney blood flow index and related laboratory tests. 3. To determine the effect of rhBNP on the final prognosis of patients, including ICU mortality and hospital mortality, ICU time, hospital stay, ventilator use time, kidney replacement therapy time, vasoactive drug dosage and time.
Study NCT04917419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Luminotherapy and /or Psychoeducation Program
Description: TO complete
Study NCT04917419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Luminotherapy and /or Psychoeducation Program
Description: TO complete
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
Study NCT05552638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telecare
Description: The University of Kentucky (UK) will embed telehealth stations at community-based senior centers. Individuals who utilize these telehealth stations will be invited to complete a demographic survey prior to their telehealth appointment. Following their appointment, they will be invited to complete a semi-structured interview with the research team. Participants who elect to use telehealth station will be doing so as telehealth visits already scheduled with patients as Standard of Care (SOC). The telehealth station in the senior center will be used to increase ease and access to telehealth should the patient/provider choose to use such an approach (for example, in instances when the patient does not have sufficient technology, internet access, or capability to operate telehealth at home).
Study NCT04965714 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04965714 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegargiminase
Description: Given IM
Study NCT04965714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study NCT05001958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation
Description: Participants will view a video of a task performed by a non-disabled actor and then the participants perform the task from the video with their weaker arm \& hand.
Study NCT04939571 — intervention group
Intervention type: OTHER
Intervention: Registry of preterm born infants with treatment-requiring ROP
Description: All prematurely born infants who develop treatment requiring ROP and are treated (independent of the kind of treatment modality) at a center that participates in the registry are eligible for database entry.
Study NCT05257564 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Determine the accuracy of quantitative measurements of GLU, HbA1c,CHOL and CRE with POC devices compared to a laboratory reference method (Roche)
Description: Fingerstick capillary blood will be collected according to each manufacturer's Instructions for use. The fingerstick capillary blood samples will be used immediately on the point-of-care assays. The venous blood will be collected in specific tubes for plasma (GLU), for whole blood (HbA1c) and for serum (CREP, CHOL). Plasma will be separated by centrifugation at the PHC facility and health post and aliquots will be prepared. Serum will be left to clot prior to centrifugation and serum aliquots will be prepared at the PHC facility and health post. The samples will be stored until transfer to the BPKIHS reference lab.
Study NCT05449262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional resistance training GROUP A
Description: Session of 45-60 min. Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching
Study NCT05449262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional resistance training GROUP B
Description: Session of 45-60 min Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching
Study NCT06291207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-224A
Description: PO, Once daily, 8weeks
Study NCT06291207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-224B
Description: PO, Once daily, 8weeks
Study NCT06291207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-224C
Description: PO, Once daily, 8weeks
Study NCT06291207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of AD-224A
Description: PO, Once daily, 8weeks
Study NCT06291207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of AD-224A
Description: PO, Once daily, 8weeks
Study NCT06291207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of AD-224B
Description: PO, Once daily, 8weeks
Study NCT06291207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of AD-224B
Description: PO, Once daily, 8weeks
Study NCT06291207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of AD-224C
Description: PO, Once daily, 8weeks
Study NCT05684614 — intervention group
Intervention type: OTHER
Intervention: Negative mood induction procedure
Description: The negative mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce negative mood: 1) Velten's tasks, consisting of interactive phrase formulations with negative thoughts and beliefs about the self (e.g., I don't have any future); 2) visualizing International Affective Pictures; and 3) recalling a negative autobiographical memory related to a significant loss (e.g., a person, a pet).
Study NCT05684614 — intervention group
Intervention type: OTHER
Intervention: Spontaneous emotion regulation task
Description: Participants are instructed to use whatever strategy they want by doing, saying, and/or thinking whatever they want to feel better for 2 min
Study NCT05684614 — intervention group
Intervention type: OTHER
Intervention: Positive mood induction procedure
Description: The positive mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce positive mood: 1) Velten's tasks, consisting of interactive phrase formulations with positive thoughts and beliefs (e.g., Life is wonderful); 2) visualizing International Affective Pictures; and 3) recalling a positive autobiographical memory
Study NCT05085405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician notification
Description: An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual.
Study NCT05085405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Notification with Nurse Facilitation
Description: An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual.
Study NCT05085405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Notification / Patient Activation
Description: An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk.
Study NCT05085405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Notification with Nurse Facilitation / Patient Activation
Description: An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk.
Study NCT06358703 — intervention group
Intervention type: DRUG
Intervention: Caplacizumab
Description: Early Caplacizumab use
Study NCT05206435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Cigarette
Description: Electronic Cigarettes are provided to replace tobacco cigarettes
Study NCT05206435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Lozenge
Description: Nicotine Lozenges are provided to replace tobacco cigarettes
Study NCT05129384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: B. infantis EVC001 or Lactose Placebo
Description: Infant probiotic
Study NCT05129384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B. infantis EVC001 or Lactose Placebo
Description: Infant probiotic
Study NCT00803088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Alair System
Description: Treatment of airways with the Alair System
Study NCT05424692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate
Description: Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
Study NCT04920448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Administered as specified in the treatment arm
Study NCT04827537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20-hydroxyecdysone Oral
Description: 100 mg (one pill) x two times a day orally, 10 consecutive days
Study NCT04827537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Oral
Description: 500 mg (one pill) x two times a day orally, 10 consecutive days
Study NCT04827537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral
Description: 100 mg (one pill) x two times a day orally, 10 consecutive days
Study NCT06304727 — intervention group
Intervention type: OTHER
Intervention: clinical data review
Description: Medical records review to gather and analyze demographic, clinical, care and virological data
Study NCT05888337 — intervention group
Intervention type: DEVICE
Intervention: Contoura LASIK with Phorcides planning strategy
Description: Bilateral treatment with topography guided LASIK
Study NCT05888337 — intervention group
Intervention type: DEVICE
Intervention: Contoura LASIK with manifest refraction planning strategy
Description: Bilateral treatment with topography guided LASIK
Study NCT05250726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MENISC-T
Description: Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of meniscus used as interposition at the STT joint
Study NCT04912531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Realty using a Microsoft Hololens, Empatica HR wristband, and EEG
Description: The investigators will use a DeepReality VR with biofeedback using a Microsoft Hololens, Empatica HR wristband and EEG. The Empatica HR wristband will measure HR and the EEG will measure alpha and theta brain waves. To monitor the physiologic data in real-time, data from the EEG and heart rate monitor will be streamed and processed in an Android Application that the investigators previously developed. During data collection, the Android app sends data via OSC to a specific IP and port, which is then collected in the game engine, Unity 3D and processed to adapt the virtual environment. Importantly, each device is inexpensive and can be sanitized and reused by multiple patients.
Study NCT04912531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Essence Olfactory Necklace
Description: The Essence Olfactory Necklace holds a small, lightweight 7 ml capsule that contains an essential oil. Within the capsule is a piezo electric transducer which allows us to control the release of scent via Bluetooth using a smartphone app. Each Essence Necklace will be paired with a google phone that the investigators will use to control the frequency and intensity of scent for each patient. The investigators will limit the frequency to one burst of scent every 20 seconds to avoid habituation. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water). The investigators chose lavender because in our previous studies, >97% of users enjoyed the lavender scent. The Essence Necklace is powered with a 3.7V Lithium Battery and has a battery lifetime of approximately 6 hours. The RC can easily recharge the Essence Necklace through a USB micro connector. Additionally, the Essence Necklace can be easily sanitized and reused by multiple patients.
Study NCT04912531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bedside Olfaction Device
Description: The bedside olfaction device can be clipped on to the side of the patient's bed or beside table. The RC will turn on the night-time olfactory device at 7 pm and will turn off the device at 7 am. When turned on, the device releases scent once every 60 seconds. However, the frequency and intensity of the scent will be adjusted to the patient's preferences. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water).
Study NCT05093166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ex vivo expanded autologous human oral epithelium containing stem cells
Description: The treatment includes a single administration of investigational product through a dedicated surgical procedure of penis wound bed preparation, epithelial surface adaption and product application followed by urethra tubularization and penis reconstruction.
Study NCT05128448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-body stretch (CBS)
Description: CBS is a self administered stretch that aims to stretch posterior shoulder structures
Study NCT05128448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilisation with movement (MWM)
Description: WMW is a musculoskeletal procedure that aims to improve restricted and/or painful range of movement
Study NCT05933876 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR).
Description: Analyze clinical data, medical images and molecular circulating features to propose which variables serve to select the patients that will achieve complete response after SABR.
Study NCT05933876 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: To propose a diagnostic test to determine the effectiveness of SABR.
Description: Collect blood samples at five different time points before and after treatment and analyze circulating tumoral DNA, medical images, and metabolites to monitor the effect of SABR and its effectiveness.
Study NCT05933876 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: To propose a diagnostic test for Oligometastatic Cancer (OC).
Description: Analyze circulating tumoral DNA and metabolites from blood samples in search of the profile of OC.
Study NCT04981262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stimulance
Description: Intervention with Prebiotic supplement
Study NCT05966922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Stimulation
Description: Electrical Stimulation and a sham will be administered through the skin in random consecutive sessions in a study group. A single monophasic square electrical pulse and transcutaneous electrical nerve stimulation will be applied to the forearm volar aspect.
Study NCT03625973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3D-RT
Description: Objects printed using 3D printing media will be used as stimuli in Reminiscence Therapy
Study NCT06389591 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)
Description: pp65 RNA loaded lipid particles or pp65 RNA-LPs administered intravenously
Study NCT06389591 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)
Description: personalized tumor mRNA, pp65 fl LAMP mRNA and DOTAP liposomes or RNA loaded lipid particles, RNA-LPs administered intravenously
Study NCT05268120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.
Description: Both first choice treatments in Dutch guideline for MRSA decolonization
Study NCT05268120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.
Description: Both first choice treatments in Dutch guideline for MRSA decolonization
Study NCT04679376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 40 mg daily administered orally in tablet or capsule form
Study NCT06465602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: The subjects will receive 1.5 grams per day of Nicotinamide, orally, for 30 days.
Study NCT06465602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will receive 1.5 grams per day of placebo, orally, for 30 days.
Study NCT03625973 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RT-Verbal
Description: Verbal cues will be used as stimuli in Reminiscence Therapy